# US 2025/0376501 A1 · Recombinant binding protein targeting tslp and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0376501 A1
- Document ID: US20250376501A1
- Status: Published application
- Kind: A1
- Application number: 18/876,668
- Filed: 2022-06-29
- Published: 2025-12-11
- Earliest claimed: 2022-06-29
- Assignees: Jingyuan Biosciences (Suzhou) Co., Ltd.
- Applicants: Jingyuan Biosciences (Suzhou) Co., Ltd.
- Inventors: Xiaobo CHEN; Linghua GUO; Yunqiu YAN; Wenzheng QIAN; Hui CHAI; Minxiang LIU
- Web page: https://patentgrep.com/patent/US20250376501A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/7155: {for interleukins [IL]}
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are a recombinant binding protein targeting TSLP and the use thereof. The recombinant binding protein comprises at least one ankyrin repeat domain that specifically binds to TSLP, wherein the ankyrin repeat domain comprises three tandem binding domains, and each binding domain comprises four binding active regions. The recombinant binding protein of the present invention has excellent binding activity to TSLP, and effectively blocks the interaction between TSLP and a receptor thereof, thereby effectively controlling TSLP-related diseases.

## Claims

### Claim 1

A recombinant binding protein targeting TSLP, comprising at least one ankyrin repeat domain that specifically binds to TSLP;
the ankyrin repeat domain comprises three tandem binding domains; the amino acid sequence of the binding domain is as shown in SEQ ID NO: 22; or,
the recombinant binding protein targeting TSLP comprises at least one ankyrin repeat domain that specifically binds to TSLP; the ankyrin repeat domain comprises three tandem binding domains, and each binding domain comprises four binding active sites; wherein the three binding domains are a first binding domain, a second binding domain, and a third binding domain in tandem; the first binding domain, the second binding domain, the third binding domain, and a fourth binding domain each comprise a first binding active site, a second binding active site, a third binding active site, and a fourth binding active site in tandem; the amino acid sequence of the first binding active site of the first binding domain is as shown in SEQ ID NO: 10, the amino acid residue of the second binding active site is Y or D, the amino acid sequence of the third binding active site is YN, VV, or FS, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the second binding domain is as shown in SEQ ID NO: 11, the amino acid residue of the second binding active site is M, the amino acid sequence of the third binding active site is PF, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the third binding domain is as shown in SEQ ID NO: 12 or SEQ ID NO: 13, the amino acid residue of the second binding active site is K, the amino acid sequence of the third binding active site is FV, and the amino acid residue of the fourth binding active site is N.

### Claim 2 (depends on 1)

The recombinant binding protein according to claim 1, wherein the amino acid sequence of the binding domain is as shown in any one of SEQ ID NOs: 23 to 28.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The recombinant binding protein according to claim 1, wherein at least one ankyrin repeat domain of the recombinant binding protein has the amino acid sequence as shown in SEQ ID NO: 1, 7, or 8; or, the recombinant binding protein comprises two, three, or four ankyrin repeat domains.

### Claim 5 (depends on 1)

A fusion protein targeting TSLP, comprising the recombinant binding protein according to claim 1 and a structurally stable protein; the structurally stable protein is used for prolonging the in vivo plasma half-life of the recombinant binding protein.

### Claim at position 6

6-8. (canceled)

### Claim 9 (depends on 1)

A recombinant cell comprising the recombinant binding protein according to claim 1 or a fusion protein;
wherein the fusion protein comprises the recombinant binding protein and a structurally stable protein; the structurally stable protein is used for prolonging the in vivo plasma half-life of the recombinant binding protein.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the recombinant binding protein according to claim 1 or a fusion protein, and a pharmaceutically acceptable carrier;
wherein the fusion protein comprises the recombinant binding protein and a structurally stable protein; the structurally stable protein is used for prolonging the in vivo plasma half-life of the recombinant binding protein.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A drug box kit comprising a drug box A and a drug box B;
the drug box A comprises the recombinant binding protein according to claim 1 or a fusion protein; the drug box B comprises other therapeutic agents;
wherein the fusion protein comprises the recombinant binding protein and a structurally stable protein; the structurally stable protein is used for prolonging the in vivo plasma half-life of the recombinant binding protein.

### Claim 14 (depends on 1)

A method for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease, comprising administering to a patient in need thereof an effective amount of the recombinant binding protein according to claim 1 or a fusion protein;
wherein the fusion protein comprises the recombinant binding protein and a structurally stable protein; the structurally stable protein is used for prolonging the in vivo plasma half-life of the recombinant binding protein.

### Claim 15

A recombinant binding protein targeting TSLP, comprising at least one ankyrin repeat domain that specifically binds to human TSLP; the recombinant binding protein is capable of specifically binding to human TSLP, thereby blocking the formation of a complex among TSLP, TSLPR, and hIL-7Rα;
wherein the ankyrin repeat domain binds at least to one or more amino acid residues selected from D18, E20, K21, L27, S28, and S43 in the amino acid sequence as shown in SEQ ID NO: 17.

### Claim 16 (depends on 2)

The recombinant binding protein according to claim 2, wherein the three tandem binding domains are a first binding domain, a second binding domain, and a third binding domain, respectively; wherein the amino acid sequence of the first binding domain is as shown in SEQ ID NO: 23, SEQ ID NO: 26, or SEQ ID NO: 27; the amino acid sequence of the second binding domain is as shown in SEQ ID NO: 24; the amino acid sequence of the third binding domain is as shown in SEQ ID NO: 25 or SEQ ID NO: 28.

### Claim 17 (depends on 16)

The recombinant binding protein according to claim 16, wherein the ankyrin repeat domain further comprises an N-terminal capping region and a C-terminal capping region; the amino acid sequence of the N-terminal capping region is as shown in SEQ ID NO: 29, the amino acid sequence of the C-terminal capping region is as shown in SEQ ID NO: 21.

### Claim 18 (depends on 17)

The recombinant binding protein according to claim 17, wherein the amino acid sequence of the N-terminal capping region is as shown in any one of SEQ ID NOs: 18 to 20.

### Claim 19 (depends on 1)

The recombinant binding protein targeting TSLP according to claim 1, wherein the amino acid sequence of the first binding active site of the first binding domain is as shown in SEQ ID NO: 10, the amino acid residue of the second binding active site is Y, the amino acid sequence of the third binding active site is YN, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the second binding domain is as shown in SEQ ID NO: 11, the amino acid residue of the second binding active site is M, the amino acid sequence of the third binding active site is PF, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the third binding domain is as shown in SEQ ID NO: 12, the amino acid residue of the second binding active site is K, the amino acid sequence of the third binding active site is FV, and the amino acid residue of the fourth binding active site is N; or,
the amino acid sequence of the first binding active site of the first binding domain is as shown in SEQ ID NO: 10, the amino acid residue of the second binding active site is D, the amino acid sequence of the third binding active site is VV, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the second binding domain is as shown in SEQ ID NO: 11, the amino acid residue of the second binding active site is M, the amino acid sequence of the third binding active site is PF, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the third binding domain is as shown in SEQ ID NO: 13, the amino acid residue of the second binding active site is K, the amino acid sequence of the third binding active site is FV, and the amino acid residue of the fourth binding active site is N; or
the amino acid sequence of the first binding active site of the first binding domain is as shown in SEQ ID NO: 10, the amino acid residue of the second binding active site is D, the amino acid sequence of the third binding active site is FS, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the second binding domain is as shown in SEQ ID NO: 11, the amino acid residue of the second binding active site is M, the amino acid sequence of the third binding active site is PF, and the amino acid residue of the fourth binding active site is H; the amino acid sequence of the first binding active site of the third binding domain is as shown in SEQ ID NO: 13, the amino acid residue of the second binding active site is K, the amino acid sequence of the third binding active site is FV, and the amino acid residue of the fourth binding active site is N.

### Claim 20 (depends on 19)

The recombinant binding protein targeting TSLP according to claim 19, wherein the binding domain further comprises a framework site; the framework site comprises a first framework site, a second framework site, a third framework site, and a fourth framework site sequentially; the binding activity site and the framework site are arranged with intervals; wherein the amino acid residue of the first framework site is G, the amino acid sequence of the second framework site is as shown in SEQ ID NO: 14, the amino acid sequence of the third framework site is as shown in SEQ ID NO: 15, and the amino acid sequence of the fourth framework site is shown as SEQ ID NO: 16.

### Claim 21 (depends on 20)

The recombinant binding protein targeting TSLP according to claim 20, wherein the N-terminus and C-terminus of the ankyrin repeat domain further comprise a capping sequence; wherein the amino acid sequence of the capping sequence at the N-terminus is as shown in SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20; the amino acid sequence of the capping sequence at the C-terminus is as shown in SEQ ID NO: 21.

### Claim 22 (depends on 9)

A drug box kit comprising a drug box A and a drug box B;
the drug box A comprises the recombinant cell according to claim 9; the drug box B comprises other therapeutic agents.

### Claim 23 (depends on 11)

A drug box kit comprising a drug box A and a drug box B;
the drug box A comprises the pharmaceutical composition according to claim 11; the drug box B comprises other therapeutic agents.

### Claim 24 (depends on 9)

A method for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease, comprising administering to a patient in need thereof an effective amount of the recombinant cell according to claim 9.

### Claim 25 (depends on 11)

A method for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 11.

### Claim 26 (depends on 13)

A method for preventing or treating an autoimmune disease, an inflammatory disease, or an allergic disease, comprising administering to a patient in need thereof an effective amount of the drug box kit according to claim 13.

### Claim 27 (depends on 14)

The method according to claim 14, wherein the autoimmune disease is selected from rheumatoid arthritis and multiple sclerosis; the inflammatory disease is selected from ulcerative colitis, eosinophilic esophagitis, chronic obstructive pulmonary disease, and psoriasis; the allergic disease is selected from atopic dermatitis, allergic rhinitis, allergic conjunctivitis, asthma, and allergic sinusitis.
